Xortx Therapeutics Inc. Stock
Price
Target price
€2.26
€2.26
-0.440%
-0.01
-0.440%
-
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Xortx Therapeutics Inc. Stock
Xortx Therapeutics Inc. shows a slight decrease today, losing -€0.010 (-0.440%) compared to yesterday.
Our community identified positive and negative aspects for Xortx Therapeutics Inc. stock for the coming years. 0 users see the criterium "Worthwhile Investment for the next years" as a plus for the Xortx Therapeutics Inc. stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.
Pros and Cons of Xortx Therapeutics Inc. in the next few years
Pros
?
B****
?
S********** s********
?
M***** P*******
Cons
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
News
XORTX Reprices Warrants Issued in Connection with Previous Private Placements
CALGARY, AB - April 30, 2024 - XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on
XORTX Announces Publication of Key Research in ADPKD
CALGARY, AB – April 22, 2024 – XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ), a late-stage clinical pharmaceutical company
XORTX Welcomes New Member to the Board of Directors
CALGARY, AB – April 8, 2024 – XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ), a late-stage clinical pharmaceutical company